NGAL expression is elevated in both colorectal adenoma-carcinoma sequence and cancer progression and enhances tumorigenesis in xenograft mouse models

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4331-4340

  Sun, Yan ^a,b   Yokoi, Kenji ^b   Li, Hui ^a   Gao, Jun ^a   Hu, Limei ^b   Liu, Ben ^a   Chen, Kexin ^a   Hamilton, Stanley R ^b   Fan, Dominic ^b   Sun, Baocun ^a   Zhang, Wei ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CECUM; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPLEEN; TISSUE MICROARRAY; TUMOR LOCALIZATION; TUMOR VOLUME;

ACUTE-PHASE PROTEINS; ADENOMA; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOCALINS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECURRENCE; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960314350     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0226     Document Type: Article

References (39)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
3. Ilyas M, Straub J, Tomlinson IP, Bodmer WF. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999;35:1986-2002. (Pubitemid 30026220)
4. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011;29:17-24.
5. Sanjoaquin MA, Choodari-Oskooei B, Dolbear C, Putcha V, Sehgal A, Key TJ, et al. Colorectal cancer incidence, mortality and survival in South-east England between 1972 and 2001. Eur J Cancer Prev 2007;16:10-6.
6. Triebel S, Blaser J, Reinke H, Tschesche H. A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 1992;314:386-8. (Pubitemid 23005695)
7. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425-32. (Pubitemid 23150227)
8. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002;10:1033-43. (Pubitemid 36001971)
9. Gwira JA, Wei F, Ishibe S, Ueland JM, Barasch J, Cantley LG. Expression of neutrophil gelatinase-associated lipocalin regulates epithelial morphogenesis in vitro. J Biol Chem 2005;280:7875-82. (Pubitemid 40349684)
10. Bratt T. Lipocalins and cancer. Biochim Biophys Acta 2000;1482:318-26.
11. Zerega B, Cermelli S, Michelis B, Cancedda R, Cancedda FD. Expression of NRL/NGAL (neu-related lipocalin/neutrophil gelatinase-associated lipocalin) during mammalian embryonic development and in inflammation. Eur J Cell Biol 2000;79:165-72. (Pubitemid 30179500)
12. Bolignano D, Donato V, Lacquaniti A, Fazio MR, Bono C, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 2010;288:10-6.
13. Tong Z, Wu X, Ovcharenko D, Zhu J, Chen CS, Kehrer JP. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J 2005;391:441-8. (Pubitemid 41532443)
14. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005;11:5390-5. (Pubitemid 41060812)
15. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, et al. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A 2009;106:3913-8.
16. Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, et al. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res 2009;69:8579-84.
17. Kubben FJ, Sier CF, Hawinkels LJ, Tschesche H, van Duijn W, Zuidwijk K, et al. Clinical evidence for a protective role of lipocalin- 2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer 2007;43:1869-76. (Pubitemid 47238246)
18. Zhang H, Xu L, Xiao D, Xie J, Zeng H, Wang Z, et al. Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J Clin Pathol 2007;60:555-61. (Pubitemid 46867169)
19. Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer 2007;120:2426-34. (Pubitemid 46642130)
20. Tong Z, Kunnumakkara AB, Wang H, Matsuo Y, Diagaradjane P, Harikumar KB, et al. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res 2008;68:6100-8.
21. Zhang XF, Zhang Y, Zhang XH, Zhou SM, Yang GG, Wang OC, et al. Clinical significance of neutrophil gelatinase-associated lipocalin (NGAL) expression in primary rectal cancer. BMC Cancer 2009;9:134.
22. Bousserouel S, Kauntz H, Gossé F, Bouhadjar M, Soler L, Marescaux J, et al. Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. Int J Oncol 2010;36:1485-90.
23. Hu L, Hittelman W, Lu T, Ji P, Arlinghaus R, Shmulevich I, et al. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest 2009;89:531-48.
24. Lee HJ, Lee EK, Lee KJ, Hong SW, Yoon Y, Kim JS. Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer 2006;118:2490-7.
25. Sun B, Sun Y, Wang J, Zhao X, Zhang S, Liu Y, et al. The diagnostic value of SYT-SSX detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH) for synovial sarcoma: a review and prospective study of 255 cases. Cancer Sci 2008;99:1355-61. (Pubitemid 351761724)
26. Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, Standop J, et al. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer 2008;98:1540-7. (Pubitemid 351652327)
27. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 1988;48:6863-71. (Pubitemid 19012219)
28. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996;38:414-20.
29. Leng X, Lin H, Ding T, Wang Y, Wu Y, Klumpp S, et al. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene 2008;27:6110-9.
30. Leng X, Ding T, Arlinghaus R. Requirement of lipocalin 2 for hematopoietic and solid tumor malignancies. Adv Enzyme Regul 2009;49:142-6.
31. Berger T, Cheung CC, Elia AJ, Mak TW. Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis. Proc Natl Acad Sci U S A 2010;107:2995-3000.
32. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001;276:37258-65.
33. Nuntagowat C, Leelawat K, Tohtong R. NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. Clin Exp Metastasis 2010;27:295-305.
34. Iannetti A, Pacifico F, Acquaviva R, Lavorgna A, Crescenzi E, Vascotto C, et al. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc Natl Acad Sci U S A 2008;105:14058-63.
35. Li SH, Hawthorne VS, Neal CL, Sanghera S, Xu J, Yang J, et al. Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation. Cancer Res 2009;69:9163-8.
36. Provatopoulou X, Gounaris A, Kalogera E, Zagouri F, Flessas I, Goussetis E, et al. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer 2009;9:390.
37. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 2008;108:389-97. (Pubitemid 351431077)
38. Du ZP, Lv Z, Wu BL, Wu ZY, Shen JH, Wu JY, et al. Neutrophil gelatinase-associated lipocalin and its receptor: independent prognostic factors of oesophageal squamous cell carcinoma. J Clin Pathol 2011;64:69-74.
39. Rousseau B, Chibaudel B, Bachet JB, Larsen AK, Tournigand C, Louvet C, et al. Stage II and stage III colon cancer: treatment advances and future directions. Cancer J 2010;16:202-9.